Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.
MARINER is a Canadian multicentre prospective, randomized clinical outcomes-based trial evaluating noninferiority of a noninvasive PET strategy compared to ICA for CAV surveillance. Patients are randomized to annual PET or ICA for CAV surveillance. Non-inferiority is assessed according to a clinical composite of death, retransplant, allograft dysfunction not related to acute rejection, and angiographic CAV associated with myocardial infarction or heart failure. Secondary outcomes include the rate of new or progressive CAV, number of ICA performed, number of ICA and PET procedural related complications, EuroQol-5 Dimension assessed patient health-related quality of life and health care resource use.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Invasive Coronary Angiography | Other | Patients in this arm will undergo annual CAV surveillance with ICA |
|
| Positron Emission Tomography | Other | Patients in this arm will undergo annual CAV surveillance with PET |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ICA | Diagnostic Test | Patients will undergo annual CAV surveillance with ICA |
|
| Measure | Description | Time Frame |
|---|---|---|
| Clinically relevant composite: Death | Date of death due to any cause | From date of randomization up to a minimum of 2 years |
| Clinically relevant composite: Retransplant | Heart retransplantation for any indication | From date of randomization up to a minimum of 2 years |
| Clinically relevant composite: Allograft Dysfunction | ≥25% decrease in left ventricular ejection fraction | From date of randomization up to a minimum of 2 years |
| Clinically relevant composite: CAV with Heart Failure or Myocardial Infarction | Angiographic evidence of CAV (ISHLT CAV 1-3) | From date of randomization up to a minimum of 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of new or progressive CAV | CAV disease severity according to ISHLT CAV 0-3 grading and/or MIT on IVUS | From date of randomization up to a minimum of 2 years |
| Number of ICA performed | Number of ICA performed for any indication including CAV surveillance, abnormal PET or clinical indication |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sharon Chih | Contact | 613-696-7000 | schih@ottawaheart.ca | |
| Heather Ross | Contact | heather.ross@uhn.ca |
| Name | Affiliation | Role |
|---|---|---|
| Sharon Chih | Ottawa Heart Institute Research Corporation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Calgary | Not yet recruiting | Calgary | Alberta | Canada |
Not provided
1:1 randomization to PET or ICA
Not provided
Not provided
Not provided
Not provided
| PET | Diagnostic Test | Patients will undergo annual CAV surveillance with PET |
|
| From date of randomization up to a minimum of 2 years |
| Number of procedural related complications (ICA and PET) | The frequency of ICA and PET procedural related complication including vascular access complications, stroke, MI, arrhythmia, drug allergy and contrast nephropathy | From date of randomization up to a minimum of 2 years |
| Patient Health related outcomes | EuroQol-5 Dimension is a standardized health related questionnaire measuring 5 domains of health and a state of health using a visual analog scale (best state marked 100 and worst state marked 0) | Baseline and 12-monthly up to a minimum of 2 years |
| Health Resource Utilization | Cost effectiveness of each CAV surveillance strategy (ICA and PET) | From date of randomization up to a minimum of 2 years |
| Mazankowski Alberta Heart Institute | Not yet recruiting | Edmonton | Alberta | Canada |
|
| University of Ottawa Heart Institute | Recruiting | Ottawa | Ontario | K1Y 4W7 | Canada |
|
| Toronto-General Hospital - University Health Network | Not yet recruiting | Toronto | Ontario | Canada |
|
| Montreal Heart Institute | Not yet recruiting | Montreal | Quebec | Canada |
|